Immune Inhibitory Mechanisms and New Insights into Ovarian Cancer Treatment
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 8499
Special Issue Editors
Interests: ovarian cancer microenvironment; immune checkpoints; tumor-infiltrating immune cells; immunotherapy
Interests: cancer immunology; macrophages; myeloid-derived suppressor cells; γδ T cells; flow cytometry
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Ovarian cancer (OC) is one of the most lethal gynecological malignancies. Its high mortality rate is a result of the lack of screening methods and specific symptoms of the disease, related to the extreme heterogeneity of OC, including genomic, transcriptomic, proteomic, and, the least understood of all, immunologic aspects. Currently, we acknowledge that the immune system plays a dual role in OC. It can not only suppress tumor growth by eliminating cancer cells or inhibiting their outgrowth, but can also promote tumor progression. OC development and progression are highly dependent on the specific tumor microenvironment (TME). Understanding how the composition of the TME changes during OC development and progression is a prerequisite for projecting therapeutic strategies to tackle the tumor at a specific evolutionary stage, which is important for the selection of the most suitable therapy.
The latest advances in the field of tumor immunology and immunotherapy emphasize that ovarian cancer cells can evade the host's immune response and stimulate tumor development by deactivation or death of crucial immune system effector cells, i.e., T cells and NK cells. One of the negative regulators of activated T cells are immune checkpoint inhibitors (ICPs), e.g., programmed cell-death receptor 1 (PD-1) and its ligands (PD-L1, PD-L2), T-cell immunoglobulin, and ITIM domain (TIGIT) and T-cell immunoglobulin-3 (TIM-3) and its ligand galectin 9 (Gal-9) axis. The co-expression status of ICPs on T cells in the OC TME is pivotal to understanding the complex immune-inhibitory mechanism. The synergistic model of action of these immune factors may be a promising target in ovarian cancer treatment.
This Special Issue of Biomedicines will present research articles and reviews exploring mechanisms of ovarian cancer escaping from immune surveillance, tissue invasion, and metastasis, and current as well as novel immune-modulating/inhibiting strategies in the treatment of OC. All scientists working in these fields are cordially invited to submit their manuscripts.
Prof. Dr. Iwona Wertel
Dr. Agnieszka A. Bojarska-Junak
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- ovarian cancer microenvironment
- tumor-infiltrating immune cells
- inflammation and ovarian cancer
- dendritic cell subsets
- monocytes/macrophages
- myeloid-derived suppressor cells
- γδ T cells
- microRNA
- immune checkpoints
- resistance to therapy
- immunotherapy of ovarian cancer
- clinical trials in ovarian cancer